Division of Takeda Pharmaceutical Co. Ltd.
Latest From Shire PLC
The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.
News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates; and Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout.
News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout; and CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates.
User fee goal date calendar for June includes AMAG’s female sexual dysfunction drug Vyleesi, new indications for Sanofi/Regeneron’s Dupixent in rhinosinusitis and Merck’s Zerbaxa in nosocomial pneumonia.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Infectious & Viral Diseases
- Neurology, Nervous System
- Shire Ltd.
- Shire Pharmaceuticals Group PLC
- North America
- Company Type
- Midsize European
- Parent & Subsidiaries
Takeda Pharmaceutical Co. Ltd.
- Baxalta Inc.
- Bikam Pharmaceuticals Inc.
- Dyax Corp.
- FerroKin Biosciences Inc.
- Fibrotech Therapeutics Pty. Ltd.
- Foresight Biotherapeutics Inc.
- Jerini AG
- Lotus Tissue Repair Inc.
- Lumena Pharmaceuticals Inc.
- Meritage Pharma Inc.
- Movetis NV
- New River Pharmaceuticals Inc.
- NPS Pharmaceuticals Inc.
- Pervasis Therapeutics Inc.
- Richwood Pharmaceutical Co. Inc.
- Roberts Pharmaceutical Corp.
- sanaplasma AG
- SARcode Bioscience Inc.
- Shire BioChem Inc.
- Shire Human Genetic Therapies AB
- Shire Human Genetic Therapies Inc.
- Shire Pharmaceuticals Ireland Ltd.
- Shire Regenerative Medicine Inc.
- ViroPharma Inc.
- Shire PLC
- Senior Management
Flemming Ornskov, MD, CEO
Thomas Dittrich, CFO
Perry Sternberg, Head, US Commercial
Andreas Busch, PhD, Head, R&D & CSO
- Contact Info
Phone: (44)(617) 349-0200
300 Shire Way
Lexington, MA 02421
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.